Skip to main content
KISQALI patient portrayal.

Identify and treat patients with confidence

KISQALI is proven to help the broadest range of patients with stage II/III HR+/HER2- eBC

Identify eligible patients like Jasmine, Erin, and Katrice today
KISQALI patient portrayal Jasmine.

Stage II (T2N1)

Find out why KISQALI is right for Jasmine

 

She was recently diagnosed with stage II (T2N1) HR+/HER2- eBC. 

KISQALI patient portrayal Erin.

Stage II (T2N0)

Find out why KISQALI is right for Erin


 She was recently diagnosed with stage II (T2N0) HR+/HER2- eBC. 

KISQALI patient portrayal Katrice.

Stage III (T2N2)

Find out why KISQALI is right for Katrice 


 She was recently diagnosed with stage III (T2N2) HR+/HER2- eBC.

NATALEE was a randomized, multicenter, open-label, phase III study of KISQALI + letrozole or anastrozole (n=2549) vs letrozole or anastrozole (n=2552) for the adjuvant treatment of men and women with stage II/III HR+/HER2- eBC. At a median follow-up of 33.3 months, with 509 iDFS (primary end point) events in the study (226 [8.9%] in the KISQALI arm and 283 [11.1%] in the NSAI-alone arm), iDFS at the 3-year landmark was 90.7% for KISQALI + NSAI vs 87.6% for NSAI alone (absolute difference 3.1%); there was a 25.1% relative reduction in the risk of an iDFS event; HR=0.749 (95% CI: 0.628-0.892).1-3

eBC=early breast cancer; HR=hazard ratio; iDFS=invasive disease-free survival; NSAI=nonsteroidal aromatase inhibitor.

References: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp. 2. Hortobagyi GN, Stroyakovskiy D, Yardley DA, et al. Ribociclib + nonsteroidal aromatase inhibitor as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival analysis from the NATALEE trial. Presented at: San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX. 3. Slamon DJ, Fasching PA, Hurvitz S, et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. Ther Adv Med Oncol. 2023;15:1-16. doi:10.1177/17588359231178125